Headline
The latest stories from AHA Today.
A new analysis prepared by Kaufman, Hall & Associates LLC and released by the AHA shows that even under the most optimistic scenario, including a smooth vaccine roll-out and reduced COVID-19 hospitalizations, 39% of hospitals would operate in the red in 2021, a marked increase over pre-pandemic…
The National Resident Matching Program matched a record 36,179 medical school seniors and graduates to U.S. residency positions, 2.6% more than last year. Applicants include students and graduates of U.S. and international medical schools.
The AHA Center for Health Innovation invites hospitals and health systems to participate in its second Hospital Community Collaborative, which will focus on COVID-19-related community needs.
The Food and Drug Administration authorized for emergency use an armband device that screens people without COVID-19 symptoms for certain potential SARS-CoV-2 biomarkers, such as excessive blood clotting.
AstraZeneca said its AZD1222 COVID-19 vaccine candidate is safe and effective, based on data culled from a phase 3 clinical trial of 32,449 U.S. patients.
The House of Representatives voted 246-175 to approve H.R. 1868, a bill that, among other health care provisions, would eliminate the 2% across-the-board cut to all Medicare payments, known as sequestration, until the end of 2021.
The Food and Drug Administration yesterday updated the health care provider fact sheets for all three monoclonal antibody therapies authorized for emergency use to include information on whether SARS-CoV-2 variants may show resistance to that therapy.
AHA urged the Centers for Medicare & Medicaid Services to extend the five-year window for building medical residency programs to account for the COVID-19 public health emergency.
The Department of Health and Human Services postponed for one year, pending judicial review, a final rule that would require the agency to assess periodically each regulation to determine whether it has a significant economic impact on a substantial number of small entities and, if so, determine…
For the first time, the Food and Drug Administration authorized marketing a SARS-CoV-2 diagnostic test beyond the public health emergency based on additional data. FDA previously authorized the BioFire Respiratory Panel 2.1 test for emergency use to detect SARS-CoV-2 and other respiratory pathogens…